Business Context and Reporting Period
This Form 8-K filing by Avalo Therapeutics, Inc. (AVTX) is dated January 30, 2024. The report addresses the Company's status regarding Nasdaq listing compliance following a prior notification of noncompliance with the minimum bid price requirement.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance status.
Material Changes
- Regulatory Status: The Company received written confirmation from Nasdaq on January 30, 2024, that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2) (Bid Price Rule).
- Stock Price: Following a reverse stock split executed on December 28, 2023, the common stock has traded above the $1.00 minimum requirement since December 29, 2023.
Outlook, Risks, and Contingencies
- Mandatory Monitoring: The Company is subject to a mandatory panel monitor for a period of one year from January 30, 2024.
- Delisting Risk: If the Company falls out of compliance with the Bid Price Rule again within this one-year period, it will not be permitted to submit a plan of compliance or receive additional cure periods. Instead, Nasdaq will issue a Delist Determination Letter, leading to a hearing panel review. Failure to satisfy the panel would result in delisting from the Nasdaq Capital Market.
Investor Verification Checklist
- Verify the current trading price of AVTX to ensure it remains above the $1.00 threshold.
- Monitor future 8-K filings for any new Nasdaq notifications regarding compliance status.
- Review the Company's capital structure and cash position in the most recent 10-Q or 10-K to assess liquidity, as this 8-K does not provide financial data.